|
1
|
Burger M, Catto JW, Dalbagni G, Grossman
HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C,
Shariat S and Lotan Y: Epidemiology and risk factors of urothelial
bladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu D, Niu X, Pan H, Zhou Y, Qu P and Zhou
J: MicroRNA-335 is downregulated in bladder cancer and inhibits
cell growth, migration and invasion via targeting ROCK1. Mol Med
Rep. 13:4379–4385. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ploeg M, Aben KK and Kiemeney LA: The
present and future burden of urinary bladder cancer in the world.
World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen WQ, Zeng HM, Zheng RS, Zhang SW and
He J: Cancer incidence and mortality in china, 2007. Chin J Cancer
Res. 24:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cornu JN, Neuzillet Y, Herve JM, Yonneau
L, Botto H and Lebret T: Patterns of local recurrence after radical
cystectomy in a contemporary series of patients with
muscle-invasive bladder cancer. World J Urol. 30:821–826. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang J, Wang S, Han F, Li J, Yu L, Zhou
P, Chen Z, Xue S, Dai C and Li Q: MicroRNA-542-3p suppresses
cellular proliferation of bladder cancer cells through
post-transcriptionally regulating survivin. Gene. 579:146–152.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaufman DS, Shipley WU and Feldman AS:
Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Borel C, Deutsch S, Letourneau A,
Migliavacca E, Montgomery SB, Dimas AS, Vejnar CE, Attar H,
Gagnebin M, Gehrig C, et al: Identification of cis- and
trans-regulatory variation modulating microRNA expression levels in
human fibroblasts. Genome Res. 21:68–73. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Phuah NH and Nagoor NH: Regulation of
microRNAs by natural agents: New strategies in cancer therapies.
Biomed Res Int. 2014:8045102014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiao J, Lin HY, Zhu YY, Zhu YP and Chen
LW: MiR-126 regulates proliferation and invasion in the bladder
cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt
signaling pathway. Onco Targets Ther. 9:5181–5193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoo HI, Kim BK and Yoon SK:
MicroRNA-330-5p negatively regulates ITGA5 expression in human
colorectal cancer. Oncol Rep. 36:3023–3029. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu K, Ma L and Zhu J: miR-483-5p promotes
growth, invasion and self-renewal of gastric cancer stem cells by
Wnt/β-catenin signaling. Mol Med Rep. 14:3421–3428. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chandrasekaran KS, Sathyanarayanan A and
Karunagaran D: MicroRNA-214 suppresses growth, migration and
invasion through a novel target, high mobility group AT-hook 1, in
human cervical and colorectal cancer cells. Br J Cancer.
115:741–751. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cortés-Sempere M and Ibáñez de Cáceres I:
microRNAs as novel epigenetic biomarkers for human cancer. Clin
Transl Oncol. 13:357–362. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mirghasemi A, Taheriazam A, Karbasy SH,
Torkaman A, Shakeri M, Yahaghi E and Mokarizadeh A: Down-regulation
of miR-133a and miR-539 are associated with unfavorable prognosis
in patients suffering from osteosarcoma. Cancer Cell Int.
15:862015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gu L and Sun W: MiR-539 inhibits thyroid
cancer cell migration and invasion by directly targeting CARMA1.
Biochem Biophys Res Commun. 464:1128–1133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lv LY, Wang YZ, Zhang Q, Zang HR and Wang
XJ: miR-539 induces cell cycle arrest in nasopharyngeal carcinoma
by targeting cyclin-dependent kinase 4. Cell Biochem Funct.
33:534–540. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Montie JE, Bahnson RR, Cohen SM, Drucker
B, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange
PH, et al: Bladder cancer. Clinical practice guidelines in
oncology. J Natl Compr Canc Netw. 3:4–5, 19–34. 2005.PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie QX, Lin XC, Zhang MF, Han CX and Guo
YH: Expression of IGF-I and IGF-IR in bladder cancer. Ai Zheng.
23:707–709. 2004.(In Chinese). PubMed/NCBI
|
|
25
|
Sun HZ, Wu SF and Tu ZH: Blockage of
IGF-1R signaling sensitizes urinary bladder cancer cells to
mitomycin-mediated cytotoxicity. Cell Res. 11:107–115. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Metalli D, Lovat F, Tripodi F, Genua M, Xu
SQ, Spinelli M, Alberghina L, Vanoni M, Baffa R, Gomella LG, et al:
The insulin-like growth factor receptor I promotes motility and
invasion of bladder cancer cells through Akt- and mitogen-activated
protein kinase-dependent activation of paxillin. Am J Pathol.
176:2997–3006. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Z, Li S, Huang K, Zhang Q, Wang J, Li
X, Hu T, Wang S, Yang R, Jia Y, et al: The nuclear protein
expression levels of SNAI1 and ZEB1 are involved in the progression
and lymph node metastasis of cervical cancer via the
epithelial-mesenchymal transition pathway. Hum Pathol.
44:2097–2105. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ran J, Lin DL, Wu RF, Chen QH, Huang HP,
Qiu NX and Quan S: ZEB1 promotes epithelial-mesenchymal transition
in cervical cancer metastasis. Fertil Steril. 103:1606–1614.e1-e2.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Osaki LH and Gama P: MAPKs and signal
transduction in the control of gastrointestinal epithelial cell
proliferation and differentiation. Int J Mol Sci. 14:10143–10161.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cao Z, Liu LZ, Dixon DA, Zheng JZ,
Chandran B and Jiang BH: Insulin-like growth factor-I induces
cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling
pathways in human ovarian cancer cells. Cell Signal. 19:1542–1553.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu H, Zhang Y, Cai XH, Huang JF and Cai L:
Changes in microRNA expression in the MG-63 osteosarcoma cell line
compared with osteoblasts. Oncol Lett. 4:1037–1042. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jin H and Wang W: MicroRNA-539 suppresses
osteosarcoma cell invasion and migration in vitro and targeting
Matrix metallopeptidase-8. Int J Clin Exp Pathol. 8:8075–8082.
2015.PubMed/NCBI
|
|
33
|
Zhang H, Li S, Yang X, Qiao B, Zhang Z and
Xu Y: miR-539 inhibits prostate cancer progression by directly
targeting SPAG5. J Exp Clin Cancer Res. 35:602016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu Q, Gong JP, Li J, Zhong SL, Chen WX,
Zhang JY, Ma TF, Ji H, Lv MM, Zhao JH and Tang JH: Down-regulation
of miRNA-452 is associated with adriamycin-resistance in breast
cancer cells. Asian Pac J Cancer Prev. 15:5137–5142. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rochester MA, Patel N, Turney BW, Davies
DR, Roberts IS, Crew J, Protheroe A and Macaulay VM: The type 1
insulin-like growth factor receptor is over-expressed in bladder
cancer. BJU Int. 100:1396–1401. 2007. View Article : Google Scholar : PubMed/NCBI
|
